Supplementary Figure S5 from Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy

Abstract

<p>Supplementary Figure S5 shows the immunohistochemical evaluation of hypoxia in NCI-H1703 subcutaneous tumor model</p>